neurological complications on disease course. Nonetheless, neuropsychological impairment has been associated with lower HRQoL scores in some studies. 4, 5 The objective of our study was to examine the impact of different neurological syndromes on HRQoL by studying HIV/AIDS patients with and without neurological disease that were matched in terms of level of immunosuppression and treatment regimens.
METHODS
The Southern Alberta Clinic is a comprehensive and centralized community outpatient HIV clinic that provides care to all HIV seropositive patients in southern Alberta, Canada with clinical assessments at regular intervals (three to four months) including antiretroviral and related medications as well as laboratory investigations (CD4/CD8 lymphocyte counts, viral loads, etc.) without patient financial cost. The present study was nested in a prospective parent study that examined the socioeconomic impact of HIV/AIDS on adults (>18 yr.). 6 Inclusion in the parent study was voluntary and independent of health status including neurological disease. Consent for participation was reviewed at the outset, which was approved by the University of Calgary Ethics Committee. Sociodemographic, clinical, and HRQoL data were collected at the initial visit and at subsequent visits at approximate 16-week intervals between 1999 and 2002. Patient HRQoL was evaluated using the Medical Outcomes Short-form Health Survey-HIV (©Albert W. Wu, Johns Hopkins University, Version 2.97), an instrument that is a 35-item questionnaire containing 11 subscales scored independently. In situations where the patient had difficulty with the instrument, the interviewer and/or caregiver assisted the patient. Higher scores on each dimension (range: 0 to 100) indicate higher levels of functioning.
Patients were selected on the basis of the presence or absence of a concurrent neurological diagnosis made by a clinical neurologist based on established criteria. 7 The Neurological Disease Group (NDG) was subdivided into the following categories: (a) HIV-related cognitive impairment including HIVassociated dementia or minor cognitive motor disorder; (b) HIVsensory neuropathy including distal sensory polyneuropathy or antiretroviral toxic neuropathy and (c) Miscellaneous NDG including seizures, migraine, mononeuritides, transient ischemic attack/stroke, tremor, which developed after the diagnosis of HIV infection. Patients who demonstrated severe cognitive impairment (Memorial Sloan Kettering dementia severity score ≥ 2) 8 were excluded from this analysis.
Neurological disease-free controls were compared to the NDG, HIV-related cognitive impairment, and HIV-sensory neuropathy groups. If multiple neurological diagnoses were assigned at different times, the date of the first neurological diagnosis was used. A subset of patients in the parent study, without neurological disease, were selected on the basis of age (>35 years), sex, education, CD4 count (<500/mm 3 ), and HIV disease duration (>36 months) as a matched control group (Controls). Statistical analyses using parametric and nonparametric tests were performed using Graph-Pad Instat version 3.0 (Graph Pad software, San Diego, CA). p values greater than 0.05 were considered nonsignificant.
RESULTS
Given that neurological disease is associated with increasing immunosuppression and age among HIV/AIDS patients and HRQoL scores decline with progressive immunosuppression, it was essential to ensure that the Control and NDG patients were similar in terms of risk factors for HIV infection, level of immunosuppression, and antiretroviral treatment. Selected Controls did not differ significantly from the NDG with respect to gender, age, HIV risk factor, ethnicity, educational level, mean CD4 nadir, duration of HIV infection and the number of patients receiving HAART (Table) . Thus, sociodemographic and clinical features of systemic disease did not differ between NDG and Control groups. Similarly, stratified NDG groups including HIVsensory neuropathy (n=41) and cognitive impairment (n=19) also did not differ in age, CD4 count, education, nor duration of infection from the Control group (data not shown). Comparisons of HRQoL dimension scores among Controls and the NDG revealed that patients with neurological syndromes exhibited significantly lower HRQoL scores in ten of 11 dimensions compared to Controls (Figure) at the onset of the study. Moreover, the HIV-sensory neuropathy group showed lower HRQoL scores compared to the Control group in all dimensions THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES 202 Figure) . To exclude any bias by selection of patients based on age, sex, education, CD4 level and duration of disease, we compared the NDG with all patients without neurological disease who had received the Medical Outcomes Short-form Health Survey-HIV questionnaire (n=200) in the parent study, revealing that patients with neurological disease scored significantly worse than controls, even when stratified by CD4 level (data not shown). Patients having multiple neurological diagnoses showed lower HRQoL scores in the dimensions of quality of life and social functioning compared to those with a single neurological diagnosis (p<0.05). Thus, these studies indicated that the HRQoL scores among HIV/AIDS patients with neurological disease were substantially lower than those from patients without neurological disease. Although the above cross-sectional studies suggested that HRQoL was reduced among HIV/AIDS patients with neurological disease, we wanted to investigate the longitudinal aspects of HRQoL in these patient groups. Prospective analysis of HRQoL dimensions ( Figure B) within the NDG group (n=36) revealed a trend of diminishing HRQoL scores (from 32 to 16 weeks) prior to the date of neurological diagnosis and implementation of appropriate treatments followed by a progressive improvement in HRQoL, beginning approximately 16 weeks after the date of neurological diagnosis until 32 weeks after the neurological diagnosis was made. Specific treatments included analgesics and antiretroviral drugs including nucleoside analogues with efficient brain penetration. This trend was evident for the dimensions of physical functioning, pain, cognitive function, overall health, energy, quality of life, and health distress while only the cognitive function dimension demonstrated a significant improvement in HRQoL scores at 48 weeks after the diagnosis of a neurological condition (p<0.05). The Control group showed no consistent changes over the 80-week period for all dimensions, indicating that HRQoL scores are sensitive to clinical intervention in patients with neurological diseases.
DISCUSSION
The present study reports the first analysis of HRQoL among HIV/AIDS patients targeting those with a range of neurological syndromes. Importantly our study was performed in a community clinic and thus, our population of interest provides a broad and representative perspective of neurological disease among HIV/AIDS patients. We demonstrate that HIV/AIDS patients with neurological syndromes have significantly lower HRQoL scores in compared to age-, sex-, disease durationmatched controls, even after controlling for the level of immunosuppression and treatment. In addition, patients with cognitive impairment consistently demonstrated the lowest HRQoL scores. The prospective analysis revealed a decline in several HRQoL dimensions prior to a neurological diagnosis and treatment implementation. This decline was followed by a trend of progressively improving HRQoL scores in these important dimensions at 16 weeks after the date of the neurological diagnosis and the initiation of specific treatments. Thus, these observations underscore the significant adverse, albeit treatable, impact of neurological disease on HRQoL in patients with HIV/AIDS.
